COVID-19 患者的 Takotsubo 综合征:系统回顾

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Xiaojia Lu MD , Catherine Teng MD , Peng Cai MSc , Jing Liang MD , Yanxuan Wang MD , Hawa Abu MD, PhD , Yuan Jia Wang , John E. Madias MD , Kan Liu MD, PhD, MBA , Qi Liu PhD , Pengyang Li MD
{"title":"COVID-19 患者的 Takotsubo 综合征:系统回顾","authors":"Xiaojia Lu MD ,&nbsp;Catherine Teng MD ,&nbsp;Peng Cai MSc ,&nbsp;Jing Liang MD ,&nbsp;Yanxuan Wang MD ,&nbsp;Hawa Abu MD, PhD ,&nbsp;Yuan Jia Wang ,&nbsp;John E. Madias MD ,&nbsp;Kan Liu MD, PhD, MBA ,&nbsp;Qi Liu PhD ,&nbsp;Pengyang Li MD","doi":"10.1016/j.cjco.2024.03.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Respiratory conditions are major physical triggers of takotsubo syndrome (TTS) and portend worse outcomes. However, data on TTS in patients with coronavirus disease-2019 infection (COVID-19) are limited.</p></div><div><h3>Methods</h3><p>We searched PubMed, Embase, and Cochrane Library databases for case reports for the period 2019-2022 describing TTS in patients with COVID-19 pneumonia (TTS-COVID). We summarized the clinical data and outcomes and compared them to those in patients with TTS with an acute respiratory disease other than COVID-19 as a trigger (TTS-acute respiratory disease) and those with TTS with no respiratory disease (TTS-no respiratory disease).</p></div><div><h3>Results</h3><p>The mortality rate was higher in those with TTS-COVID (26.0%) than those with TTS-acute respiratory disease (5.7%) or TTS-no respiratory disease (4.2%; <em>P</em> &lt; 0.001 for both). The proportion of men was higher in TTS-COVID (33.3%) than it was in TTS-no respiratory disease (9.1%; <em>P</em> &lt; 0.001). The manifestations of TTS in COVID patients were atypical (dyspnea [70.3%] and cough [40.6%]); few had chest pain (23.4%). Cardiovascular risk factors were common in the TTS-COVID cohort, but fewer patients were on cardioprotective medications in this group than in the other 2 groups. Level of catecholamine use was higher in the TTS-COVID group (37.7%) than it was in the TTS-no respiratory disease (10.9%; <em>P</em> &lt; 0.001) group. Apical ballooning (72.6%) was the most common TTS subtype, and basal segment type was seen in 11.0% of TTS-COVID patients.</p></div><div><h3>Conclusions</h3><p>COVID-19 patients who developed TTS had high mortality rates and unique features, compared with those in the TTS-acute respiratory disease group or the TTS-no respiratory disease group. Understanding the pathophysiology of TTS in COVID-19 may help prevent TTS and direct therapy in this setting.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001355/pdfft?md5=58b59237bb28ae1514c9503c798a2ab6&pid=1-s2.0-S2589790X24001355-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Takotsubo Syndrome in Patients With COVID-19: A Systematic Review\",\"authors\":\"Xiaojia Lu MD ,&nbsp;Catherine Teng MD ,&nbsp;Peng Cai MSc ,&nbsp;Jing Liang MD ,&nbsp;Yanxuan Wang MD ,&nbsp;Hawa Abu MD, PhD ,&nbsp;Yuan Jia Wang ,&nbsp;John E. Madias MD ,&nbsp;Kan Liu MD, PhD, MBA ,&nbsp;Qi Liu PhD ,&nbsp;Pengyang Li MD\",\"doi\":\"10.1016/j.cjco.2024.03.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Respiratory conditions are major physical triggers of takotsubo syndrome (TTS) and portend worse outcomes. However, data on TTS in patients with coronavirus disease-2019 infection (COVID-19) are limited.</p></div><div><h3>Methods</h3><p>We searched PubMed, Embase, and Cochrane Library databases for case reports for the period 2019-2022 describing TTS in patients with COVID-19 pneumonia (TTS-COVID). We summarized the clinical data and outcomes and compared them to those in patients with TTS with an acute respiratory disease other than COVID-19 as a trigger (TTS-acute respiratory disease) and those with TTS with no respiratory disease (TTS-no respiratory disease).</p></div><div><h3>Results</h3><p>The mortality rate was higher in those with TTS-COVID (26.0%) than those with TTS-acute respiratory disease (5.7%) or TTS-no respiratory disease (4.2%; <em>P</em> &lt; 0.001 for both). The proportion of men was higher in TTS-COVID (33.3%) than it was in TTS-no respiratory disease (9.1%; <em>P</em> &lt; 0.001). The manifestations of TTS in COVID patients were atypical (dyspnea [70.3%] and cough [40.6%]); few had chest pain (23.4%). Cardiovascular risk factors were common in the TTS-COVID cohort, but fewer patients were on cardioprotective medications in this group than in the other 2 groups. Level of catecholamine use was higher in the TTS-COVID group (37.7%) than it was in the TTS-no respiratory disease (10.9%; <em>P</em> &lt; 0.001) group. Apical ballooning (72.6%) was the most common TTS subtype, and basal segment type was seen in 11.0% of TTS-COVID patients.</p></div><div><h3>Conclusions</h3><p>COVID-19 patients who developed TTS had high mortality rates and unique features, compared with those in the TTS-acute respiratory disease group or the TTS-no respiratory disease group. Understanding the pathophysiology of TTS in COVID-19 may help prevent TTS and direct therapy in this setting.</p></div>\",\"PeriodicalId\":36924,\"journal\":{\"name\":\"CJC Open\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2589790X24001355/pdfft?md5=58b59237bb28ae1514c9503c798a2ab6&pid=1-s2.0-S2589790X24001355-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CJC Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589790X24001355\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CJC Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589790X24001355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景呼吸系统疾病是诱发塔可次波综合征(TTS)的主要生理因素,并预示着更严重的后果。然而,冠状病毒病-2019感染(COVID-19)患者的TTS数据有限。方法我们检索了PubMed、Embase和Cochrane图书馆数据库中2019-2022年间描述COVID-19肺炎(TTS-COVID)患者TTS的病例报告。我们总结了临床数据和结果,并与以COVID-19以外的急性呼吸道疾病为诱因的TTS患者(TTS-急性呼吸道疾病)和无呼吸道疾病的TTS患者(TTS-无呼吸道疾病)进行了比较。结果TTS-COVID患者的死亡率(26.0%)高于TTS-急性呼吸道疾病患者(5.7%)或TTS-无呼吸道疾病患者(4.2%;两者的P均为0.001)。男性在 TTS-COVID 中所占比例(33.3%)高于 TTS 无呼吸系统疾病患者(9.1%;P <0.001)。COVID 患者的 TTS 表现不典型(呼吸困难 [70.3%] 和咳嗽 [40.6%]);胸痛患者很少(23.4%)。心血管风险因素在 TTS-COVID 组群中很常见,但与其他两组相比,该组中服用心脏保护药物的患者较少。TTS-COVID 组使用儿茶酚胺的比例(37.7%)高于 TTS 无呼吸系统疾病组(10.9%;P < 0.001)。结论与 TTS-acute respiratory disease 组或 TTS-no respiratory disease 组相比,COVID-19 患者发生 TTS 的死亡率高且具有独特特征。了解 COVID-19 中 TTS 的病理生理学有助于预防 TTS 并指导治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Takotsubo Syndrome in Patients With COVID-19: A Systematic Review

Takotsubo Syndrome in Patients With COVID-19: A Systematic Review

Background

Respiratory conditions are major physical triggers of takotsubo syndrome (TTS) and portend worse outcomes. However, data on TTS in patients with coronavirus disease-2019 infection (COVID-19) are limited.

Methods

We searched PubMed, Embase, and Cochrane Library databases for case reports for the period 2019-2022 describing TTS in patients with COVID-19 pneumonia (TTS-COVID). We summarized the clinical data and outcomes and compared them to those in patients with TTS with an acute respiratory disease other than COVID-19 as a trigger (TTS-acute respiratory disease) and those with TTS with no respiratory disease (TTS-no respiratory disease).

Results

The mortality rate was higher in those with TTS-COVID (26.0%) than those with TTS-acute respiratory disease (5.7%) or TTS-no respiratory disease (4.2%; P < 0.001 for both). The proportion of men was higher in TTS-COVID (33.3%) than it was in TTS-no respiratory disease (9.1%; P < 0.001). The manifestations of TTS in COVID patients were atypical (dyspnea [70.3%] and cough [40.6%]); few had chest pain (23.4%). Cardiovascular risk factors were common in the TTS-COVID cohort, but fewer patients were on cardioprotective medications in this group than in the other 2 groups. Level of catecholamine use was higher in the TTS-COVID group (37.7%) than it was in the TTS-no respiratory disease (10.9%; P < 0.001) group. Apical ballooning (72.6%) was the most common TTS subtype, and basal segment type was seen in 11.0% of TTS-COVID patients.

Conclusions

COVID-19 patients who developed TTS had high mortality rates and unique features, compared with those in the TTS-acute respiratory disease group or the TTS-no respiratory disease group. Understanding the pathophysiology of TTS in COVID-19 may help prevent TTS and direct therapy in this setting.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CJC Open
CJC Open Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.30
自引率
0.00%
发文量
143
审稿时长
60 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信